BCM
VOR icon

Bridgeway Capital Management’s Vor Biopharma VOR Stock Holding History

Bridgeway Capital Management’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,250
Closed -$305K – 1287
2025
Q3 		$305K Buy
+6,250
New +$251K 0.01% 925
2025
Q2 		– Sell
-6,045
Closed -$86.7K – 1273
2025
Q1 		$86.7K Sell
6,045
-585
-9% -$14K ﹤0.01% 1064
2024
Q4 		$147K Sell
6,630
-165
-2% -$2.73K ﹤0.01% 1057
2024
Q3 		$95.1K Sell
6,795
-1,500
-18% -$27.3K ﹤0.01% 1165
2024
Q2 		$166K Buy
8,295
+1,660
+25% +$53.7K ﹤0.01% 1089
2024
Q1 		$314K Sell
6,635
-1,500
-18% -$65.9K 0.01% 1030
2023
Q4 		$366K Hold
8,135
– – 0.01% 1017
2023
Q3 		$345K Buy
8,135
+3,125
+62% +$169K 0.01% 979
2023
Q2 		$310K Hold
5,010
– – 0.01% 1038
2023
Q1 		$539K Hold
5,010
– – 0.01% 867
2022
Q4 		$666K Buy
5,010
+1,040
+26% +$103K 0.02% 827
2022
Q3 		$316K Buy
3,970
+500
+14% +$49.2K 0.01% 1019
2022
Q2 		$345K Buy
+3,470
New +$355K 0.01% 964

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Bridgeway Capital Management's VOR Position: Q4 2025 in Review

Bridgeway Capital Management sold out of Vor Biopharma (VOR) in Q4 2025, closing a stake of 6,250 shares — an estimated $305K sold.

Bridgeway Capital Management first reported a position in VOR in Q2 2022 and held it in 13 quarters. The position peaked at $666K in Q4 2022. 55 funds tracked by Wall St. Rank hold VOR as of Q4 2025.

  • Bridgeway Capital Management reported no remaining Vor Biopharma position as of Q4 2025 after selling out during the quarter.
  • Bridgeway Capital Management sold 6,250 Vor Biopharma shares in Q4 2025, an estimated $305K.
  • Bridgeway Capital Management first reported a position in Vor Biopharma in Q2 2022 and held it in 13 quarters.
  • Bridgeway Capital Management's Vor Biopharma position peaked at $666K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2025.

Based on Bridgeway Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.